CN110679947A - Traditional Chinese medicine health product for reducing blood sugar - Google Patents
Traditional Chinese medicine health product for reducing blood sugar Download PDFInfo
- Publication number
- CN110679947A CN110679947A CN201911211363.9A CN201911211363A CN110679947A CN 110679947 A CN110679947 A CN 110679947A CN 201911211363 A CN201911211363 A CN 201911211363A CN 110679947 A CN110679947 A CN 110679947A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- blood sugar
- health product
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 64
- 239000008280 blood Substances 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 230000001603 reducing effect Effects 0.000 title claims abstract description 25
- 230000036541 health Effects 0.000 title claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000002552 dosage form Substances 0.000 claims abstract description 6
- 239000000047 product Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 235000013305 food Nutrition 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 241001530121 Trollius Species 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 241001312894 Trollius chinensis Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 241000612118 Samolus valerandi Species 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 241001632410 Eleutherococcus senticosus Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229960003243 phenformin Drugs 0.000 description 3
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 208000006443 lactic acidosis Diseases 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 241001149430 Auricularia auricula-judae Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine health product for reducing blood sugar, which belongs to the technical field of health products and is prepared from traditional Chinese medicine raw materials of 9 ~ 30 parts of acanthopanax, 5 ~ 20 parts of globeflower and 5 ~ 15 parts of agaric, wherein the traditional Chinese medicine and food with homology of medicine and food are compatible, so that the traditional Chinese medicine health product has small side effect, not only can achieve the effect of reducing blood sugar after being eaten for a long time, but also can effectively regulate organisms and achieve the effect of treating both symptoms and root causes, has mild characters, is an ideal health product for reducing blood sugar, has flexible dosage form, and can be prepared into more convenient dosage forms according to the requirements of different patients.
Description
Technical Field
The invention relates to a traditional Chinese medicine health product for reducing blood sugar, belonging to the technical field of health products.
Background
In recent years, the life style of people is changed, the intake of fat and sugar in diet is greatly increased, the daily exercise time is shortened by fast work, and the number of people suffering from diabetes is rapidly increased; under normal conditions, a human body can ensure the balance between the source of blood sugar and the route of arrival through two regulating systems of hormone regulation and nerve regulation, so that the blood sugar is maintained at a certain level; however, under the combined action of genetic factors (such as family history of diabetes) and environmental factors (such as unreasonable diet, obesity and the like), the two major regulatory functions are disordered, and the blood sugar level is increased; obesity is generally a common driver of the development of diabetes, with type 2 diabetes being more common; short-term and disposable hyperglycemia does not seriously damage human bodies, but long-term hyperglycemia can cause pathological changes of all tissues and organs of the whole body, and acute and chronic complications, such as dehydration, electrolyte disorder, nutrient deficiency, resistance reduction, renal function impairment, neuropathy, cardiovascular and cerebrovascular diseases, diabetic foot and the like, occur. The cost for treating diabetes is huge, and the currently used chemical synthetic drugs have obvious short-term curative effect but are not easy to take for a long time; therefore, the development of a drug which can effectively prevent and treat diabetes, has small toxic and side effects and can be used for a long time from natural products becomes a hot spot of current research.
Diabetes based on syndrome differentiation in traditional Chinese medicine belongs to the category of diabetes. The pathogenesis of the disease is mainly the deficiency of yin and fluid and severe dryness-heat, with yin deficiency as the principal factor and dryness-heat as the secondary factor. Dryness-heat occurs internally, dry fluid is dry and stagnant, and stagnant qi and blood are caused by long-term stagnation. The new prevention and treatment technologies in recent years mainly comprise islet cell transplantation, pancreas transplantation, insulin pump replacement insulin injection, immunotherapy of diabetes and the like, and clinically common treatment medicines comprise biguanide hypoglycemic medicines, namely metformin hydrochloride and phenformin (phenformin); although a mode for replacing insulin injection is found, due to slow popularization, a plurality of patients continue to inject insulin, the most direct side effect of insulin injection is hypoglycemia under the condition of improper dosage, and insulin has water retention effect and edema can be generated; furthermore, the skin of a human body can be wounded due to long-term insulin injection, and hard lumps are generated around the navel of most people and are not easy to eliminate for a long time, so that the life quality of a patient is greatly reduced. The main side effect of Jiangtangling is gastrointestinal reaction, and the Jiangtangling has symptoms of anorexia, bitter taste in mouth, nausea, vomit, diarrhea and the like, and is easy to induce lactic acidosis due to liver metabolism. Although the potential of metformin to induce lactic acidosis is significantly reduced compared to phenformin, this side effect is still present. Therefore, how to keep the blood sugar of the diabetes patients stable for a long time needs to develop a blood sugar reducing product with stable curative effect, less side effect and small side effect and treating both symptoms and root causes.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a traditional Chinese medicine health care product for reducing blood sugar, which can reduce the blood sugar index of a patient with hyperglycemia and improve the body condition to ensure that the blood sugar index is within a normal range; can also regulate body functions, is mainly used for treatment and is stable, safe and effective.
The technical scheme for solving the technical problems is that the traditional Chinese medicine health product for reducing blood sugar is prepared from the following traditional Chinese medicine raw materials, by weight, 9 ~ 30 parts of acanthopanax, 5 ~ 20 parts of globeflower and 5 ~ 15 parts of agaric.
The traditional Chinese medicine composition is preferably prepared from the following traditional Chinese medicine raw materials in parts by weight: 25 parts of acanthopanax, 15 parts of trollflower and 10 parts of agaric.
A preparation method of a traditional Chinese medicine health product for reducing blood sugar comprises the following steps:
adding 8 ~ 12 times of distilled water into the traditional Chinese medicine raw materials, soaking until the materials are thoroughly mixed, decocting for 1 ~ 3 times, each time decocting for 1 ~ 3 hours, mixing the decoctions, filtering to remove slag while the decoction is hot, concentrating the filtrate until a small amount of liquid is hung on the wall, performing vacuum freeze drying for 48 hours to obtain a powder formulation, and storing in a low-temperature drying environment to obtain the traditional Chinese medicine health product for reducing blood sugar.
The dosage form of the hypoglycemic traditional Chinese medicine health product can also be decoction, granules, capsules, tablets, powder, paste, oral liquid or solid beverage.
The blood sugar reducing health care product is prepared by matching traditional Chinese medicines (acanthopanax senticosus), traditional Chinese medicines (trollflower) and food (edible fungus).
Acanthopanax Senticosus Saponin (ASS) has effects of reducing blood sugar of experimental diabetic rat, and has close relation with improving activity of anti-oxygen free radical enzymes and resisting peroxidation injury. ASS can increase insulin secretion of type II diabetic rats, and has protective effect on pancreatic B cells. The syringin in radix Acanthopanacis Senticosi has effects of lowering blood sugar, and increasing glycogen synthesis rate. The acanthopanax root is used for treating diabetes, can relieve symptoms of thirst, deficiency and fatigue of patients and the like, lowers urine glucose and blood sugar, and has stable curative effect.
In traditional Chinese medicine, diabetes is classified into diabetes and is consistent with the basic pathogenesis of heat generation of the diabetes, namely heat injury to qi and yin, the pathogenic fire and heat are the most common in the excess pathogenic factors, and the dryness-heat is generated internally. Trollius chinensis bunge is a heat-clearing and toxicity-removing drug commonly used in the north. Has effects in clearing away heat and toxic materials, cooling blood, nourishing yin, promoting salivation, and quenching thirst. A series of complications and serious infection easily appear after the patient suffers from diabetes, if the long-term blood sugar control is not good, the organism regulating function of the patient with long-term chronic hyperglycemia is damaged, the glucotoxicity effect is caused, the eyeground blood vessel of the eye or the cornea of the eye can be damaged, and the injury of the eye is caused. Recorded in gang mu Shi Yi (compendium for remains), the globeflower can cure aphtha, larynx swelling, ear pain due to heat and edema, eye pain, improving eyesight and relieving glaucomias. The Chinese medicine has the concepts of 'prevention before illness' and 'prevention and change after illness' from ancient times, so that the trollius chinensis bunge is used for assisting in controlling diabetes and complications thereof, and can play a better role in reducing blood sugar. The above results show that the trollius chinensis bunge can be used for preventing and treating diabetes, so that the trollius chinensis bunge is selected for preventing and treating diabetic complications such as diabetic foot and the like.
The Auricularia auricula polysaccharide in-vitro hydrolysate (AAOS) can promote GLP-1 secretion of STZ diabetic rats, improve pancreatic island function and improve blood sugar regulation capability; the activity of SOD, CAT and GR in serum is greatly influenced, and the capability of eliminating free radicals of diabetic rats can be improved; can reduce TG level and LDL-C level of diabetic rats by regulating lipid metabolism, and has positive effect in preventing and treating diabetic complication deterioration.
The researches show that the acanthopanax senticosus has a good effect of improving hyperglycemia, the trollius chinensis bunge can be used for assisting in treating a series of diabetic complications and infections, the agaric can be used for adjusting insulin level and resisting oxidative stress, the acanthopanax senticosus, the trollius chinensis bunge and the agaric are flexibly combined to reduce blood sugar according to the basic theory of traditional Chinese medicine, and various components are matched with each other to achieve the effects of promoting insulin secretion of organisms, improving activity of anti-oxygen free radical enzymes, promoting synthesis of glycogen and improving energy conservation of blood sugar regulation.
The invention has the beneficial effects that: a traditional Chinese medicine health product for reducing blood sugar is prepared by taking traditional Chinese medicines and medicinal and edible foods as main raw materials according to the physical characteristics of patients with hyperglycemia according to the theory of traditional Chinese medicine, so as to regulate and control the blood sugar content in human bodies, and gradually reduce the dosage of hypoglycemic and anti-aging medicines and insulin by conditioning; based on the traditional Chinese medicine disease treatment theory, the invention regulates the metabolism of the digestive system in vivo by regulating the functions of the spleen, the stomach, the liver and the kidney, thereby controlling the sugar content in blood and achieving good effects of reducing and controlling blood sugar; has good blood sugar reducing effect on diabetes of different pathogenesis such as upper-jiao, middle-jiao and lower-jiao; the traditional Chinese medicine and the food with homology of medicine and food are compatible, so that not only can the effect of reducing blood sugar be achieved after long-term eating, but also the organism can be effectively regulated, and the effect of treating both principal and secondary aspect of disease can be achieved; and the health-care product has mild properties, stable curative effect and small side effect, is an ideal health-care product for reducing blood sugar, and has flexible dosage form, good effect and convenient taking.
Detailed Description
The present invention will be further described with reference to the following embodiments.
Example one
Adding distilled water in an amount which is 10 times the weight of the raw materials of 25 parts of acanthopanax, 15 parts of trollius chinensis and 10 parts of agaric, soaking until the mixture is thoroughly soaked, then decocting for 2 times, decocting for 2 hours each time, combining the decoctions, filtering to remove residues while the mixture is hot, concentrating the filtrate until a small amount of liquid is hung on the wall, and carrying out vacuum freeze drying for 48 hours to obtain powder; storing the powder in a low-temperature dry environment to obtain the traditional Chinese medicine health product for reducing blood sugar.
Dosage form and drinking mode:
① adding warm water to dissolve the above powder for direct drinking;
② adding pharmaceutically acceptable carrier or excipient, mixing, and making into solid beverage or granule, subpackaging into 3 ~ 10g each bag, dissolving in warm water, and drinking directly;
③ mixing above powders with adjuvant, and making into capsule or tablet for oral administration;
④ the stock solution can be concentrated and added with quantitative additives to make into paste with good taste 5 ~ 15 ml per bag, or packaged into bottles to make into oral liquid for direct drinking.
Example two
1. Experimental animals:
50 mice
2. Reagent:
tetraoxypyrimidine, glucose and blood sugar kit
3. Experimental drugs:
adding 10 parts of distilled water into 25 parts of acanthopanax, 15 parts of trollius chinensis and 10 parts of agaric, soaking until the mixture is thoroughly mixed, decocting for 2 times, decocting for 2 hours each time, mixing decoctions, filtering to remove residues while the mixture is hot, and concentrating to obtain a stomach filling volume containing 1 time, 3 times and 5 times of the original medicine;
4. the molding method comprises the following steps:
in adult mice, 20 animals were randomly fasted for 4 hours, and fasting blood glucose was measured as the initial blood glucose value of the batch of mice. The animal model is fasted for 12 hours, water is freely drunk, alloxan 200mg/kg is injected into abdominal cavity, after 72 hours, the blood sugar is measured, and the fasting blood sugar value is more than or equal to 11.1mmol/L, so the animal model with hyperglycemia succeeds;
5. detection indexes are as follows:
body weight, fasting glucose, glucose tolerance
6. The experimental method comprises the following steps:
except for the blank group, hyperglycemic mice were divided into 1 model control group and 3 dose groups (high, medium, low) at random, with blood glucose levels being 4 hours after fasting. The high, medium and low dose groups were given (1-fold, 3-fold, 5-fold) concentrations of the drug solutions, and the model control group and the blank group were given equal amounts of distilled water, fasting for 30 consecutive days for 4 hours to measure fasting blood glucose values, and blood glucose values and percent blood glucose reductions were compared for each group of animals.
The animals of each group were fasted for 4 hours, blood glucose values were measured, high, medium and low dose drug solutions were administered (1, 3, 5 times) in concentration, equivalent amounts of distilled water were administered to the model control group and the blank group, glucose was administered orally at 2.0g/kg in each group after 20 minutes, blood glucose values at 0, 0.5 and 2 hours in each group after glucose administration were measured, and changes in blood glucose values and areas under the blood glucose curves after glucose administration (0, 0.5 and 2 hours) in the model control group and the test sample group were observed.
Note: p <0.05, p <0.01 when compared to the model group, p <0.05, p <0.01 when compared to the blank control group
Except for the blank group, the body weight of the mice in the other groups is slowly increased compared with the blank group, and has a very significant difference (P < 0.01). After 30 days of administration, the body weight growth trend of mice in the low, medium and high dose groups is obvious compared with that in the model group, and the medium and high dose groups show a significant difference (P < 0.05) compared with that in the model group.
Note: p <0.05, p <0.01 when compared to the model group, p <0.05, p <0.01 when compared to the blank control group
The blood sugar of each group of mice before molding is normal without significant difference. After modeling, the blood sugar level of the modeled mice is obviously increased compared with that of a blank group, and the model mice show a very significant difference (P < 0.01). After administration for 30 days, the blood sugar of mice in each administration group shows a stable descending trend, the low, medium and high dose groups have statistical significance (P <0.05 or P < 0.01) compared with the model group, and show a certain dose-effect relationship, and the blood sugar descending percentage of each dose group is higher than that of the model group.
Note: p <0.05, p <0.01 when compared to the model group, p <0.05, p <0.01 when compared to the blank control group
Before the oral glucose tolerance of the mice is measured, the blood glucose of the mice in the model group is obviously increased compared with the rest groups, and the blood glucose shows a significant or extremely significant difference (P <0.05 or P < 0.01) compared with the rest groups. After the intragastric administration of the glucose solution for 0.5 h, the blood sugar level of each group is obviously increased, the blood sugar level of each group is averagely decreased after 2 h, the blood sugar of each administration group is obviously lower than that of the model group, and the low, medium and high dose groups have statistical significance (P <0.05 or P < 0.01) compared with the model group and present a certain dose-effect relationship. The areas under the curves of the low, medium and high dose groups are all smaller than those of the model group and have statistical significance (P <0.05 or P < 0.01).
The results show that the product has obvious improvement on the symptoms of the diabetes model mice and has the effect of reducing blood sugar of the diabetes model mice. And the test result of the animal with the auxiliary blood sugar reducing function can be judged to be positive without influencing the fasting blood sugar of normal animals.
Although the embodiments of the present invention have been described above, the contents thereof are merely embodiments adopted to facilitate understanding of the technical aspects of the present invention, and are not intended to limit the present invention. It will be apparent to persons skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (4)
1. The traditional Chinese medicine health product for reducing blood sugar is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight of acanthopanax 9 ~ 30, trollflower 5 ~ 20 and agaric 5 ~ 15.
2. The traditional Chinese medicine health product for reducing blood sugar according to claim 1, which is characterized in that: the weight parts of the traditional Chinese medicine raw materials are as follows: 25 parts of acanthopanax, 15 parts of trollflower and 10 parts of agaric.
3. The preparation method of the hypoglycemic traditional Chinese medicine health product according to claim 1 or 2, which is characterized in that: the method comprises the following steps:
adding 8 ~ 12 times of distilled water into the traditional Chinese medicine raw materials, soaking until the materials are thoroughly soaked, then decocting for 1 ~ 3 times, each time for 1 ~ 3 hours, combining the decoctions, and filtering to remove residues while the decoction is hot;
concentrating the filtrate to liquid with a small amount of wall hanging, vacuum freeze drying for 48h, freeze drying into powder, and storing in low temperature drying environment to obtain the traditional Chinese medicine health product for reducing blood sugar.
4. The preparation method of the hypoglycemic traditional Chinese medicine health product according to claim 3, characterized in that: the dosage form of the hypoglycemic traditional Chinese medicine health product can also be decoction, granules, capsules, tablets, paste juice, oral liquid or solid beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911211363.9A CN110679947A (en) | 2019-12-02 | 2019-12-02 | Traditional Chinese medicine health product for reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911211363.9A CN110679947A (en) | 2019-12-02 | 2019-12-02 | Traditional Chinese medicine health product for reducing blood sugar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110679947A true CN110679947A (en) | 2020-01-14 |
Family
ID=69117816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911211363.9A Pending CN110679947A (en) | 2019-12-02 | 2019-12-02 | Traditional Chinese medicine health product for reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110679947A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101585506A (en) * | 2008-05-22 | 2009-11-25 | 刘文才 | Prescription of acanthopanax health preserving pillow and child cloth toy filling material |
| CN102178008A (en) * | 2011-04-02 | 2011-09-14 | 肖立权 | Health-care nourishing tea capable of relieving blood pressure, blood fat and blood sugar |
| CN103251107A (en) * | 2013-05-31 | 2013-08-21 | 丛多明 | Drink and preparation method thereof |
| CN106474170A (en) * | 2016-11-30 | 2017-03-08 | 哈尔滨珍宝制药有限公司 | A kind of acanthopanax combination, preparation and its detection method |
| CN109276591A (en) * | 2018-11-28 | 2019-01-29 | 吉林修正药业新药开发有限公司 | Wilsonii Radix Angelicae Sinensis Milkvetch root composition auxiliary hyperglycemic new application |
-
2019
- 2019-12-02 CN CN201911211363.9A patent/CN110679947A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101585506A (en) * | 2008-05-22 | 2009-11-25 | 刘文才 | Prescription of acanthopanax health preserving pillow and child cloth toy filling material |
| CN102178008A (en) * | 2011-04-02 | 2011-09-14 | 肖立权 | Health-care nourishing tea capable of relieving blood pressure, blood fat and blood sugar |
| CN103251107A (en) * | 2013-05-31 | 2013-08-21 | 丛多明 | Drink and preparation method thereof |
| CN106474170A (en) * | 2016-11-30 | 2017-03-08 | 哈尔滨珍宝制药有限公司 | A kind of acanthopanax combination, preparation and its detection method |
| CN109276591A (en) * | 2018-11-28 | 2019-01-29 | 吉林修正药业新药开发有限公司 | Wilsonii Radix Angelicae Sinensis Milkvetch root composition auxiliary hyperglycemic new application |
Non-Patent Citations (1)
| Title |
|---|
| 权伍荣等: "刺五加对糖尿病动物模型的降血糖影响初探", 《畜牧与饲料科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN110679947A (en) | Traditional Chinese medicine health product for reducing blood sugar | |
| CN112438397A (en) | Medicated diet for people with hyperglycemia | |
| CN115120684A (en) | Traditional Chinese medicine formula for treating diabetes and processing method thereof | |
| CN113648380A (en) | Composition for treating diabetes | |
| CN102614359A (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN111298052A (en) | Medicine for treating diabetes | |
| WO2021007933A1 (en) | Application of maggots in treatment of diabetes | |
| CN110507707A (en) | A kind of Chinese medicine composition and preparation method thereof for treating type II diabetes | |
| CN110876717A (en) | Preparation method of product capable of stabilizing blood sugar | |
| CN104984331A (en) | Solution preparation using biological active multienzyme to restore pancreatic beta-cells and preparation method thereof | |
| CN115779046B (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and application for preventing and treating diabetes | |
| CN102198174A (en) | Traditional Chinese medicine formulated preparation for nourishing kidney, removing heat from liver, reducing sugar and regulating fat, and preparation method thereof | |
| CN108114268A (en) | A kind of Chinese medicine composition for reducing blood glucose, preparation and preparation method and application | |
| CN116392567B (en) | Traditional Chinese medicine composition for improving testicle dysfunction and preparation method and application thereof | |
| CN117018105B (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| CN110755523B (en) | Composition for improving hyperglycemia and preparation method thereof | |
| CN114712481B (en) | Composite plant source polypeptide and preparation method and application thereof | |
| CN106728502A (en) | A kind of hypoglycemic medicinal liquor and its production method | |
| CN107252038A (en) | A kind of functional food suitable for diabetic population | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN114451554A (en) | Composition for reducing blood sugar and dispelling effects of alcohol and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |